These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 28473598)

  • 41. FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery.
    Arnett AL; Packard AT; Mara K; Mansfield AS; Wigle DA; Haddock MG; Park SS; Olivier KR; Garces YI; Merrell KW
    Pract Radiat Oncol; 2017; 7(6):e531-e541. PubMed ID: 28733185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical respiratory motion correction software (reconstruct, register and averaged-RRA), for
    Bouyeure-Petit AC; Chastan M; Edet-Sanson A; Becker S; Thureau S; Houivet E; Vera P; Hapdey S
    Br J Radiol; 2017 Feb; 90(1070):20160549. PubMed ID: 27936893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak.
    Laffon E; Lamare F; de Clermont H; Burger IA; Marthan R
    Eur Radiol; 2014 Aug; 24(8):1964-70. PubMed ID: 24895030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study.
    Akamatsu G; Ikari Y; Nishida H; Nishio T; Ohnishi A; Maebatake A; Sasaki M; Senda M
    J Nucl Med Technol; 2015 Sep; 43(3):222-6. PubMed ID: 26271802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
    Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
    J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Test-Retest Reproducibility of
    Kurland BF; Peterson LM; Shields AT; Lee JH; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2019 May; 60(5):608-614. PubMed ID: 30361381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
    Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
    Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.
    Aristophanous M; Yong Y; Yap JT; Killoran JH; Allen AM; Berbeco RI; Chen AB
    Radiother Oncol; 2012 Mar; 102(3):377-82. PubMed ID: 22265731
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Performance of ¹⁸F-FDG PET/MRI and ¹⁸F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients.
    Sawicki LM; Grueneisen J; Buchbender C; Schaarschmidt BM; Gomez B; Ruhlmann V; Wetter A; Umutlu L; Antoch G; Heusch P
    J Nucl Med; 2016 Apr; 57(4):582-6. PubMed ID: 26742715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Normal FDG distribution patterns in the head and neck: PET/CT evaluation.
    Nakamoto Y; Tatsumi M; Hammoud D; Cohade C; Osman MM; Wahl RL
    Radiology; 2005 Mar; 234(3):879-85. PubMed ID: 15734938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
    Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.